CD44 and cancer: The majority of head and neck tumours expresses CD44, a cancer stem-like antigen, for which targeting moAbs are currently under investigation in phase 1 clinical trials (Rupp et al., 2007; Sauter et al., 2007; Tijink et al., 2006; Menke-van der Houven van Oordt et al., 2016).